The changing landscape in the treatment of metastatic castration-resistant prostate cancer

被引：33

作者：

El-Amm, Joelle ^{[1
]}

Aragon-Ching, Jeanny B. ^{[1
]}

机构：

[1] George Washington Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Washington, DC 20037 USA

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2013年 / 5卷 / 01期

关键词：

Androgen deprivation therapy; chemotherapy; metastatic castration-resistant prostate cancer; vaccine therapy; MITOXANTRONE PLUS PREDNISONE; RANDOMIZED PHASE-II; SIPULEUCEL-T; DOUBLE-BLIND; ANTITUMOR-ACTIVITY; BONE METASTASES; SURVIVAL; DOCETAXEL; MEN; TRIAL;

D O I：

10.1177/1758834012458137

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The past few years have brought increasing advances in the therapeutic management of metastatic castration-resistant prostate cancer with the approval of several agents, including vaccine therapy with sipuleucel-T, second-line chemotherapy with cabazitaxel, the bone-targeted pharmaceutical denosumab, and the novel antiandrogen therapy abiraterone acetate. There are ongoing developments with other agents in the pipeline such as MDV3100 and alpharadin that have shown promising results. This review describes the clinical trials that brought about the drug approvals of various agents and offers some insights regarding a rational approach to optimal treatment sequencing for these drugs since national guidelines are currently lacking.

引用

页码：25 / 40

页数：16

共 67 条

[11] Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer [J].

Chi, Kim N. ;

Hotte, Sebastien J. ;

Yu, Evan Y. ;

Tu, Dongsheng ;

Eigl, Bernhard J. ;

Tannock, Ian ;

Saad, Fred ;

North, Scott ;

Powers, Jean ;

Gleave, Martin E. ;

Eisenhauer, Elizabeth A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4247-4254

[12]

Chi KN, 2001, CLIN CANCER RES, V7, P3920

[13] ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment [J].

Clegg, Nicola J. ;

Wongvipat, John ;

Joseph, James D. ;

Tran, Chris ;

Ouk, Samedy ;

Dilhas, Anna ;

Chen, Yu ;

Grillot, Kate ;

Bischoff, Eric D. ;

Cal, Ling ;

Aparicio, Anna ;

Dorow, Steven ;

Arora, Vivek ;

Shao, Gang ;

Qian, Jing ;

Zhao, Hong ;

Yang, Guangbin ;

Cao, Chunyan ;

Sensintaffar, John ;

Wasielewska, Teresa ;

Herbert, Mark R. ;

Bonnefous, Celine ;

Darimont, Beatrice ;

Scher, Howard I. ;

Smith-Jones, Peter ;

Klang, Mark ;

Smith, Nicholas D. ;

De Stanchina, Elisa ;

Wu, Nian ;

Ouerfelli, Ouathek ;

Rix, Peter J. ;

Heyman, Richard A. ;

Jung, Michael E. ;

Sawyers, Charles L. ;

Hager, Jeffrey H. .

CANCER RESEARCH, 2012, 72 (06) :1494-1503

[14]

Crawford ED, 2012, ONCOLOGY-NY, V26, P70

[15] Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer [J].

Danila, Daniel C. ;

Heller, Glenn ;

Gignac, Gretchen A. ;

Gonzalez-Espinoza, Rita ;

Anand, Aseem ;

Tanaka, Erika ;

Lilja, Hans ;

Schwartz, Lawrence ;

Larson, Steven ;

Fleisher, Martin ;

Scher, Howard I. .

CLINICAL CANCER RESEARCH, 2007, 13 (23) :7053-7058

[16] Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer [J].

de Bono, Johann S. ;

Scher, Howard I. ;

Montgomery, R. Bruce ;

Parker, Christopher ;

Miller, M. Craig ;

Tissing, Henk ;

Doyle, Gerald V. ;

Terstappen, Leon W. W. M. ;

Pienta, Kenneth J. ;

Raghavan, Derek .

CLINICAL CANCER RESEARCH, 2008, 14 (19) :6302-6309

[17] Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].

De Bono, Johann S. ;

Logothetis, Christopher J. ;

Molina, Arturo ;

Fizazi, Karim ;

North, Scott ;

Chu, Luis ;

Chi, Kim N. ;

Jones, Robert J. ;

Goodman, Oscar B., Jr. ;

Saad, Fred ;

Staffurth, John N. ;

Mainwaring, Paul ;

Harland, Stephen ;

Flaig, Thomas W. ;

Hutson, Thomas E. ;

Cheng, Tina ;

Patterson, Helen ;

Hainsworth, John D. ;

Ryan, Charles J. ;

Sternberg, Cora N. ;

Ellard, Susan L. ;

Flechon, Aude ;

Saleh, Mansoor ;

Scholz, Mark ;

Efstathiou, Eleni ;

Zivi, Andrea ;

Bianchini, Diletta ;

Loriot, Yohann ;

Chieffo, Nicole ;

Thian Kheoh ;

Haqq, Christopher M. ;

Scher, Howard I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005

[18] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial [J].

de Bono, Johann Sebastian ;

Oudard, Stephane ;

Ozguroglu, Mustafa ;

Hansen, Steinbjorn ;

Machiels, Jean-Pascal ;

Kocak, Ivo ;

Gravis, Gwenaelle ;

Bodrogi, Istvan ;

Mackenzie, Mary J. ;

Shen, Liji ;

Roessner, Martin ;

Gupta, Sunil ;

Sartor, A. Oliver .

LANCET, 2010, 376 (9747) :1147-1154

[19] A REEVALUATION OF NONHORMONAL CYTO-TOXIC CHEMOTHERAPY IN THE TREATMENT OF PROSTATIC-CARCINOMA [J].

EISENBERGER, MA ;

SIMON, R ;

ODWYER, PJ ;

WITTES, RE ;

FRIEDMAN, MA .

JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (06) :827-841

[20] Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study [J].

Fizazi, Karim ;

Carducci, Michael ;

Smith, Matthew ;

Damiao, Ronaldo ;

Brown, Janet ;

Karsh, Lawrence ;

Milecki, Piotr ;

Shore, Neal ;

Rader, Michael ;

Wang, Huei ;

Jiang, Qi ;

Tadros, Sylvia ;

Dansey, Roger ;

Goessl, Carsten .

LANCET, 2011, 377 (9768) :813-822

← 1 2 3 4 5 6 7 →